How Exposomics Can Improve Clinical Trials and Precision Medicine
Why do promising drugs fail in Phase III clinical trials? Why do patients respond differently to the same therapy across countries? And if genetics only explains part of disease risk, what information is missing?
In this episode of ChatGJP, Tom Cohen, President of Panome Bio, discusses how exposomics helps answer these questions by measuring the environmental chemicals that influence human biology. He explains how environmental exposures can affect drug absorption, metabolism, signaling pathways, and the microbiome, making them an important factor in patient response and clinical trial outcomes.
Have a Question?
Your privacy is important to us.
We’ll never share your information.